Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month!

Download the guide here and see the difference!

Jennifer Lew Biography and Net Worth

CFO of Annexon

Ms. Lew joined Annexon Biosciences as Chief Financial Officer in June 2019. She previously served as Chief Financial Officer for Aduro Biotech, Inc. While at Aduro, Ms. Lew played a leadership role in the company’s preparation and execution of its initial public offering and provided financial and strategic oversight in areas of fundraising, investor relations, strategic planning and board governance. Prior to Aduro, Ms. Lew held various roles at Dynavax Technologies Corporation from 2004 to October 2013, most recently as Vice President of Finance and Principal Accounting Officer, where she was responsible for finance and accounting operations. Before joining Dynavax, Ms. Lew held positions as Assistant Controller and Director of Finance at QRS Corporation, a publicly-held technology company, from 2000 to 2004. Ms. Lew began her career in the audit practice at Ernst & Young from 1994 to 1999. She earned a B.A. in Economics/Accounting and Government from Claremont McKenna College and is a Certified Public Accountant (inactive status).

What is Jennifer Lew's net worth?: The estimated net worth of Jennifer Lew is at least $96,551.00 as of February 13th, 2023. Ms. Lew owns 29,708 shares of Annexon stock worth more than $96,551 as of June 7th. This net worth evaluation does not reflect any other assets that Ms. Lew may own. Learn More about Jennifer Lew's net worth.
How old is Jennifer Lew?: Ms. Lew is currently 49 years old. There are 5 older executives and no younger executives at Annexon. The oldest executive at Annexon is Dr. Arnon Rosenthal Ph.D., Founder, who is 66 years old. Learn More on Jennifer Lew's age.
How do I contact Jennifer Lew?: The corporate mailing address for Ms. Lew and other Annexon executives is , , . Annexon can also be reached via phone at 650-822-5500 and via email at [email protected]. Learn More on Jennifer Lew's contact information.
Has Jennifer Lew been buying or selling shares of Annexon?: Jennifer Lew has not been actively trading shares of Annexon during the last quarter. Most recently, Jennifer Lew sold 1,742 shares of the business's stock in a transaction on Monday, February 13th. The shares were sold at an average price of $6.31, for a transaction totalling $10,992.02. Following the completion of the sale, the chief financial officer now directly owns 29,708 shares of the company's stock, valued at $187,457.48. Learn More on Jennifer Lew's trading history.
Who are Annexon's active insiders?: Annexon's insider roster includes Sanjay Keswani (EVP), Jennifer Lew (CFO), Douglas Love (CEO), and Ted Yednock (EVP). Learn More on Annexon's active insiders.
Are insiders buying or selling shares of Annexon?: During the last twelve months, Annexon insiders bought shares 2 times. They purchased a total of 2,753,988 shares worth more than $10,062,313.92. During the last twelve months, insiders at the sold shares 2 times. They sold a total of 3,243 shares worth more than $20,448.32. The most recent insider tranaction occured on May, 25th when Major Shareholder Bain Capital Life Sciences Inv bought 300,000 shares worth more than $639,000.00. Insiders at Annexon own 19.1% of the company. Learn More about insider trades at Annexon.
Information on this page was last updated on 5/25/2023.

Jennifer Lew Insider Trading History at Annexon

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/13/2023	Sell	1,742	$6.31	$10,992.02	29,708
9/13/2021	Sell	3,500	$20.01	$70,035.00
5/27/2021	Sell	3,500	$22.24	$77,840.00	5,500
3/23/2021	Sell	5,000	$28.44	$142,200.00	7,000
7/28/2020	Buy	2,000	$17.00	$34,000.00

Jennifer Lew Buying and Selling Activity at Annexon

Annexon Company Overview

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Today's Range

Now: $3.12

$3.10

$3.39

50 Day Range

MA: $4.70

$2.10

$6.37

2 Week Range

Now: $3.12

$2.07

$7.65

Volume

1,617,754 shs

Average Volume

685,122 shs

Market Capitalization

$165.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.5

How A.I. Could Make Most 21st Century Diseases EXTINCT

From Behind the Markets | Ad

On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...

Get the name of the stock now... before it's too late

Jennifer Lew Biography and Net Worth

What is Jennifer Lew's net worth?

How old is Jennifer Lew?

How do I contact Jennifer Lew?

Has Jennifer Lew been buying or selling shares of Annexon?

Who are Annexon's active insiders?

Are insiders buying or selling shares of Annexon?